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Neurobiology of Disease
Active -Amyloid Immunization Restores Spatial Learning
in PDAPPMice Displaying Very Low Levels of -Amyloid
Guiquan Chen,1 Karen S. Chen,2Dione Kobayashi,2 Robin Barbour,2 RuthMotter,2Dora Games,2 Stephen J. Martin,1
and Richard G. M. Morris1
1Laboratory for Cognitive Neuroscience, Centre for Cognitive and Neural Systems, Edinburgh EH8 9JZ, United Kingdom, and 2Elan Pharmaceuticals, South
San Francisco, California 94080
The behavioral and biochemical impact of active immunization against human-amyloid (A) was assessed usingmale transgenic (Tg)
mice overexpressing a humanmutant amyloid precursor protein (heterozygous PDAPPmice) and littermate controls. Administration of
aggregated A42 occurred at monthly intervals from 7 months (“prevention”) or 11 months (“reversal”), followed by double-blind
behavioral training at 16months on a cued task, then serial spatial learning in a watermaze. Using a 2 2 design, with A42 adjuvanted
with MPL-AF (adjuvant formulation of monophosphoryl lipid A) or MPL-AF alone, PDAPPmice were impaired compared with non-Tg
littermates on two separate measures of serial spatial learning. Immunization caused no overall rescue of learning but limited the
accumulation of total A and A42 levels in cortex and hippocampus by up to 60%. In immunized PDAPP mice, significant negative
correlations were observed between hippocampal and cortical A levels and learning capacity, particularly in the prevention study, and
correlations between learning capacity and antibody titer. Moreover, a subset of PDAPPmice with very low A levels (hippocampal A
levels of6000 ng/g or cortical A levels of1000 ng/g) was indistinguishable fromnon-Tg controls.Mice in the prevention studywere
also rescued from cognitive impairment more effectively than those in the reversal study. The combination of variability in antibody
response and differential levels of A accumulation across the population of immunized PDAPPmicemay be responsible for success in
cognitive protection with only a subset of these animals, but the similarity to the findings of certain human vaccination trials is
noteworthy.
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Introduction
Several animal models of Alzheimer’s disease (AD) have been
developed to help understand the neural mechanisms of the dis-
ease process and to provide platforms for testing novel therapeu-
tics (Bartus et al., 1982; Price et al., 1992; Sisodia, 1992; Games et
al., 1995; Duff et al., 1996; Hsiao et al., 1996; Bartus, 2000; Som-
mer et al., 2000). Because abnormal accumulation of -amyloid
(A), A oligomers, and/or amyloid plaque deposition are each
held to play distinctive roles in the neurodegeneration that char-
acterizes various stages of AD, A has become a particularly im-
portant therapeutic target (Hardy andAllsop, 1991; Selkoe, 1991,
2002).
Schenk et al. (1999)made the novel suggestion of immunizing
against the accumulation of A. They observed that amyloid
plaque deposition in old PDAPP mice could be prevented when
A42 was administered monthly from 2 to 13 months of age and
significantly reduced when administered from 11 months of age
for 7 months. A antibodies apparently cross the blood–brain
barrier, bind to plaques, and activate microglial cells that clear
amyloid plaques (Bard et al., 2000). This process has been visu-
alized in the living mouse brain (Bacskai et al., 2001). Alterna-
tively, binding to A antibodies might generate a peripheral sink
(DeMattos et al., 2001), changing the equilibrium between the
neurons and plasma to aid the removal of A. Active and passive
A immunotherapy have since received widespread attention for
possible use in humans (Mattson and Chan, 2003; Nicoll et al.,
2003). A “double-blind” clinical trial that was suspended prema-
turely because of meningoencephalitis in 6% of the patients
(Schenk, 2002; Orgogozo et al., 2003) revealed reduced plaque
deposition in brain tissue (Nicoll et al., 2003) and a positive rela-
tionship between antibody titer and a lower rate of decline of
cognitive function (Gilman et al., 2005).
Several preclinical studies of the impact of immunization on
learning andmemory in amyloid precursor protein (APP) trans-
genicmice have shown positive effects. TgCRND8mice (express-
ing a mutant human APP695 gene) and non-Tg controls were
immunized with A42 from 6 weeks of age for 14 weeks (Janus et
al., 2000). A longitudinal design was used with a standard water
maze spatial reference memory task. Although still impaired rel-
ative to non-Tg controls, A-immunized Tgmice escaped signif-
icantly faster than controls during acquisition and showed re-
duced A plaque deposition. However, neither genotype nor
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immunization affected posttraining probe tests thatmeasure spa-
tial memory.Morgan et al. (2000) also used a longitudinal design
with a radial-arm water maze with untreated non-Tg, A-
immunized, or keyhole limpet hemocyanin (KLH)-immunized
Tgmice. Before treatment, all three groups displayed good learn-
ing at 11.5 months. The animals were retested at 15.5 months
after five inoculations at monthly intervals of either A or KLH.
The A-immunized Tg mice showed successful learning almost
but not quite as good as the non-Tg mice. The improved rate of
learning was explained in terms of reduced levels of soluble A in
the brain, but the number of subjects per group was small. In
studies using passive immunization with A antibodies, positive
effects have been seen in object recognition memory in 24-
month-old PDAPPmice (Dodart et al., 2002) and in water-maze
learning using other transgenic mouse models of AD (Kotilinek
et al., 2002; Billings et al., 2005; Hartman et al., 2005; Maier et al.,
2006; Wilcock et al., 2006).
The aimof this studywas twofold. First, using a large cohort of
mice to ensure adequate statistical power, we tested whether ac-
tive A immunization could prevent and/or rescue the age-
related learning deficit that is observed in PDAPP mice using a
serial spatial learning task (Chen et al., 2000). This is a useful new
behavioral protocol because, like the radial water-maze task, it
engages both encoding and retrieval of memory each day, analo-
gous to the episodic memory tasks that are susceptible in early
AD. Second, like the clinical study of Gilman et al. (2005), we also
examined whether any cognitive rescue would be related to the
impact of immunization on A levels and/or A titer responses.
We anticipated that there may be such a relationship because
variation in A levels in PDAPP mice that massively overexpress
mutant APPmight not always result in immunization-associated
rescue in every animal. In experiment 1 (“prevention”), A im-
munization of both PDAPP and non-Tg mice was started at 7
months and given at monthly intervals for 9 months. In experi-
ment 2 (“reversal”), PDAPP mice were immunized from 11
months of age for 5 months. After these treatments with A42
plus the adjuvant MPL-AF or adjuvant only, serial spatial learn-
ing was examined at 15–16 months together with later measure-
ments of A levels and A titer responses.
Materials andMethods
Subjects. All mice (n 150) were age-matched littermates. The founder
of PDAPPmicewas generated on a SwissWebsterB6D2F1 (C57BL/6
DBA/2) background (Games et al., 1995). They were bred with mice of
the same background for three generations. Generation 3 was bred with
B6D2F1. Generation 4 was then bred with Swiss Webster to generate
heterozygous animals used for the present study. All PDAPP mice were
non-white heterozygous males. In the prevention study (experiment 1),
67mice were tested (PDAPP immunized, n 17; PDAPP adjuvant only,
n 17; non-Tg immunized, n 17; non-Tg adjuvant only, n 16). In
the reversal study (experiment 2), 83 mice were tested (PDAPP immu-
nized, n  24; PDAPP adjuvant only, n  18; non-Tg immunized, n 
22; non-Tg adjuvant only, n 19). The mice were group housed (two to
four per cage). All phases of the study were conducted blind: the experi-
menter (G.C.) was blind to both genotype and treatment status, the
preliminary data analyses was conducted by someone unconnected with
the daily training of the animals (S.J.M.), the posttraining immunologi-
cal analyses conducted at Elan Pharmaceuticals (South San Francisco,
CA) was blind to the behavioral data, and the project leader (R.G.M.M.)
was blind to the outcome until all testing was complete.
The water maze. The open-field water maze is 2 m in diameter and set
into a large laboratory room with prominent two- and three-
dimensional extramaze cues. The water is filled and drained daily, main-
tained at 25°C, andmade opaque by the addition of 250ml of latex liquid
(Cementone-Beaver, Buckingham, UK). Escape from the water was pro-
vided by a single moveable platform of 20 cm diameter (ratio of pool to
platform area of 100:1) that was normally hidden 1.5 cm beneath the
water surface but, during the initial cue training, rendered visible by the
addition of a prominent local cue. The mice were gently placed into the
water facing the side walls and allowed to swim for up to 90 s to find and
climb onto the platform. The starting position was randomized and
counterbalanced. Once found, they stayed there for 30 s and were then
removed by allowing them to jump onto a small paint roller for return to
their “transport cage” in which they were placed under a heat lamp.
Several mice were trained successively in a group enabling intertrial in-
tervals to be 10min. For each location trained, the escape platformwas in
any one of 20 different locations (two series of 10 counterbalanced plat-
form locations). The swimming movements of the mice were tracked
using in-house software (Actimetrics Watermaze; Coulbourn Instru-
ments, Allentown, PA), which provides objective, automated video
tracking of the animals and a suite of relevant analysis options, including
swim path, time spent in target quadrant, thigmotaxis, etc.
Overview of experimental protocol. The two experiments were proce-
durally identical and consisted of the following phases: (1) immuniza-
tion; (2) shipping of the animals to Edinburgh; (3) visible platform train-
ing (5 d); (4) serial spatial learning with a hidden platform (10–20 d); (5)
ELISAs for total A and A42 quantification; and (6) A antibody titer
response measurement.
Phase 1: immunization of the mice. A peptide was freshly prepared
from lyophilized powder for each set of injections. For A immuniza-
tions, 2 mg of human A42 (US Peptides, Rancho Cucamonga, CA) was
added to 0.9 ml of deionized water, and the mixture was vortexed to
generate a relatively uniform suspension. A 100ml of aliquot of 10 PBS
(in which 1 PBS is 0.15 M NaCl and 0.01 M sodium phosphate, pH 7.5)
was added. The suspension was vortexed again and incubated overnight
at 37°C for use the next day. A42 at 50 mg and 25 mg of the adjuvant
MPL-AF in 200 ml of PBS were used for each subcutaneous injection.
Injections of A42 and MPL-AF or of MPL-AF alone were made on days
0, 14, and 28 and then once every 4 weeks.
Phase 2: shipping. The mice were shipped by air from San Francisco to
Edinburghwith a journey time of24 h, followed by 1week (minimum)
of acclimatization to the new housing conditions and diet, as required by
United Kingdom Project License requirements to minimize stress.
Phase 3: visible cue task training. There were 5 d of training, four trials
per day, with the platform location changed across trials. Curtains were
drawn around the pool to exclude the extramaze cues. The platform was
made visible by putting a bronze cylinder on it (15 cm high and 3 cm in
diameter). If a mouse failed to get to the platform after 90 s had elapsed,
it was guided to the visible platform by hand.
Phase 4: serial spatial reversal learning with a hidden escape platform.
The animals were trained for eight trials per day on a series of spatial tasks
(“problems”) each consisting of finding the hidden escape platform in
the water maze. Training continued until three successive trials occurred
with a mean escape latency of 20 s, a criterion that might be reached
within 1 d or might take1 d to be reached (Fig. 1). Once criterion was
reached, training for that day stopped and the animals were switched to a
new problem (i.e., new platform location) starting on the next day.
Training continued until a minimum of five separate problems had been
learned or 10 d of training, whichever took longer. Two performance
measures were derived. “Trials-to-criterion” is a quantitative assessment
of the number of trials, inclusive of the criterion run, taken to learn each
of the first five spatial locations (as in Fig. 1). “Learning capacity” is a
measure of the number of separate locations that an individual mouse
learned in 10 d of training. Bothmeasures show comparable sensitivity to
age-related changes in PDAPP mice in cross-sectional and longitudinal
experimental protocols (Chen et al., 2000).
Phase 5: ELISA analysis of total A and A42. All 150 mice tested in the
water maze were killed by cervical dislocation. The brain was quickly
removed andput into ice-cold artificial CSF. Twobrain areas, hippocam-
pus and cortex, were dissected, weighed, and then put into Eppendorf
tubes for homogenization. Guanidine buffer at 5 M was added to each
tube, and the tissue was completely homogenized with a hand-held ho-
mogenizer. The brain homogenates were further diluted 1:10 with ice-
cold casein buffer (0.25% casein, 0.05% sodium azide, 20 g/ml aproti-
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nin, 5 mM EDTA, pH 8.0, and 10 g/ml
leupeptin in PBS) before centrifugation
(16,000 g for 20 min at 4°C).
The “total” A sandwich ELISA consists of
the capture antibody 266, which is specific to
amino acids 13–28 of A, and the biotinylated
reporter antibody 3D6, which is specific to
amino acids 1–5 of A. The A42 sandwich
ELISA uses the capture monoclonal antibody
21F12 (A33–42). Biotinylated 3D6 is also the
reporter antibody in this assay. The 266 and
21F12monoclonal antibodies were coated at 10
g/ml into 96-well immunoassay plates
(Costar, Cambridge, MA) overnight at room
temperature (RT). The plates were then aspi-
rated and blocked with 0.25% human serum
albumin in PBS buffer for at least 1 h at RT and
then stored desiccated at 4°C until use. The
plateswere rehydratedwithwash buffer (0.05%
Tween 20 in Tris-buffered saline) before use.
The samples and standards were added to the
plates and incubated at RT for 1 h. The plates were washed three or more
times with wash buffer between each step of the assay. The biotinylated
3D6, diluted to 0.5g/ml in casein assay buffer (0.25% casein and 0.05%
Tween 20, pH 7.4, in PBS), was incubated in the wells for 1 h at RT.
Avidin–horseradish peroxidase (Vector Laboratories, Burlingame, CA),
diluted 1:4000 in casein assay buffer, was added to the wells for 1 h at RT.
The colorimetric substrate slow 3,30,5,59-tetramethyl benzidine (TMB)
ELISA (Pierce, Rockford, IL) was added and allowed to react for 15 min,
after which the enzymatic reaction was stopped with addition of 1 M
H2SO4. Reaction productwas quantified using aMolecularDevices (Palo
Alto, CA) Vmax spectrophotometer measuring the difference in absor-
bance at 450 and 650 nm.
Phase 6: ELISA analysis for serum antibodies. Blood samples were col-
lected from all of the 150 mice behaviorally tested. Titers were deter-
mined by serial dilutions of sera against aggregated A42 that had been
coated onto microtiter wells. Detection used goat antimouse Ig conju-
gated to horseradish peroxidase and slow TMB (Pierce) substrate. Titers
were defined as the dilution yielding 50% of the maximal signal. All
samples and standards were assayed in duplicates.
Data analysis. All behavioral and ELISA data were analyzed using
ANOVAs and analyses of covariation. An important feature was an at-
tempt to relate behavioral performance to levels of A and antibody titer
in individual animals.
Results
The animals arrived after the shipment in good health and were
required to have a minimum period of 1 week acclimatization to
the laboratory in Scotland before testing commenced. All mice
quickly adapted to the new housing conditions without difficulty
and were housed in groups consisting of three to four littermate
males. Animals (n  150) that swam well and completed the
experiment were included in this report. A small number of ani-
mals, one to two per group and in all groups, were identified as
poor swimmers and removed from the study.
Cue task performance
Immunization did not affect cue task learning in PDAPP or
non-Tg mice. Figure 2 shows the decline in mean escape latency
from between 23 and 45 s on day 1 to mean latencies of 5–7 s by
day 5 in all groups of both the prevention (F 96.2; df 1.41/89.0;
p  0.001, Greenhouse–Geisser correction) and reversal (F 
105.9; df 1.76/138.9; p  0.001) experiments. Statistical analysis
revealed no significant immunization effect in either study (F
1.58; df 1/63; p 0.2 for prevention; F 1 for reversal), but the
PDAPP groups were significantly slower to escape overall ( p val-
ues 0.01). Highly significant groups  genotype interactions
for both the prevention and reversal studies ( p values 0.005)
reflected poorer cue task performance of the PDAPPmice on day
1 ( p values0.01) but little difference thereafter. All mice were
escaping rapidly and consistently by days 4 and 5. Thus, although
there was a transitory impairment, PDAPP mice displayed no
lasting deficit in sensorimotor function or motivation to learn.
Serial spatial learning
When transferred to the serial spatial reversal task, PDAPP mice
showed a consistent learning deficit in both the trials-to-
criterion and the learning capacity measures of performance.
Figure 3, A and B (performance on five individual spatial lo-
cations) and C and D (mean trials to criterion), shows the
performance of all mice on the first five platform locations that
were used to compute the trials-to-criterion measure. For the
prevention study, an ANOVA revealed a main transgene effect
(F  13.4; df  1/63; p  0.001) but no overall effect of immu-
nization (F  1). Similarly, in the reversal study, the ANOVA
again revealed a main transgene effect (F 29.7; df 1/79; p
0.001) but again no overall immunization effect (F 1).
The effects of A immunization on spatial learning were also
examined using the learning capacity measure, the maximum
number of locations learned in 10 d (Fig. 4). In terms of total
number of platform locations learned in 10 d, PDAPPmice were
significantly impaired relative to non-Tg mice (prevention, F 
16.9, df  1/63, p  0.001; reversal, F  46.5, df  1/79, p 
0.001). However, no overall effect of immunization was found (F
values 1). These results confirm and extend the findings ob-
Figure1. Serial spatial learning task. Themain task is training on a series of five separate spatial locations (shown), followedby
additional training for a total of 10 d (data not shown). For each problem, the hidden platform is in a different location of the pool.
The trials-to-criterion data are based on this set of five problems. Swim paths are shown for the first trial of training and for the
three criterion trials of each problem only.
Figure 2. Visible platform learning. A, There was no difference in escape latency between
the PDAPP and non-Tg groups in the prevention study. B, There was a deficit in escape latency
in the PDAPP groups on day 1 but not thereafter in the reversal study.
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tained with the trials-to-criterion measure of performance over
the first five problems trained. Thus, at this stage of the analysis,
the data appeared to indicate that A immunization of PDAPP
mice for periods of either 5 or 9 months did not rescue the age-
related impairment in serial spatial learning relative to non-Tg con-
trols.However, comparisonof theperformanceofA42-immunized
animals in theprevention and reversal studies revealedbetter behav-
ioral performance of the PDAPP mice that had received the longer
period of A42 treatment (F 5.97; df 1/39; p 0.025), our first
indication that this overall picture was deceptive.
A levels
Immunization was successful in lowering A levels. After com-
pletion of behavioral testing, A levels in the brain were mea-
sured using ELISA. Table 1 shows the total A and A42 levels in
the cortex (top) and hippocampus (bottom) of PDAPPmice that
were subject to A immunization or MPL-AF only. The pattern
across groups is similar for both total A and A42. Analysis of
the two experiments together, with immunization and treatment
period as separate factors, revealed that A immunization caused
a striking reduction in total A levels in both the cortex (F 17.9;
df 1/72; p 0.001) and hippocampus (F 9.2; df 1/72; p
0.005) and in A42 levels in both the cortex (F 24.2; df 1/75;
p  0.001) and hippocampus (F  11.1; df  1/75; p  0.005)
compared with that in age-matched MPL-AF-treated PDAPP
mice. The longer period of immunization in the prevention study
(9 months) resulted in a lower total A level than that in the
reversal study (5months) in both cortex (F 10.1; df 1/72; p
0.005; 65.2 vs 37.8%) and hippocampus (F 7.1; df 1/72; p
0.05; 45.9 vs 19.5%) and a lower level of A42 in both the cortex
(F 6.6; df 1/72; p 0.05; 54.6 vs 45.2%) and hippocampus
(F  7.1; df  1/72; p  0.05; 47.0 vs 22.9%). The absolute A
levels for the hippocampus are higher than for the cortex. These
overall reductions in A levels are substantial and highly signifi-
cant. Thus, the results from this large-scale study indicate that
active A immunization effectively suppresses A accumulation
in the brain of PDAPP mice subjected to behavioral training.
Correlations between A levels and behavioral performance
Despite immunization having no overall effect on the rate at
which PDAPPmice could learn, we examined whether there was
any correlation between A levels and behavioral performance.
Because the serial spatial learning task is hippocampal dependent
but may involve information storage in cortex and because high
mutant A levels are likely to be correlated with neuronal dys-
function, it was expected that correlations would be seen between
the behavioral performance of PDAPPmice and both hippocam-
pal and cortical A. In practice, amore complex pattern emerged.
In non-immunized PDAPP mice, there was no relationship be-
tween performance and A levels (Fig. 5). However, in treated
PDAPP animals in which the overall levels of A failed to accu-
mulate, a relationship began to emerge. In the prevention study
(Fig. 5, top row; Table 2), significant correlations were observed
between total A levels in both hippocampus and cortex with
both trials to criterion (data shown only in Table 2) and learning
capacity, the highest value being r  0.624 between learning
capacity and total A in hippocampus ( p  0.01). Because a
single data point in Figure 5, A and B, may have been dispropor-
tionately contributing to these significant correlations, Spear-
man’s rank correlations were also calculated, and both were still
significant (r  0.552, p  0.025 for cortical A; and r 
0.563, p 0.025 for hippocampal A). In the reversal study, a
similar trend was apparent (Fig. 5C,D; Table 2A). There was,
however, no correlation between performance and A levels in
MPL-AF-treated mice (Fig. 5, bottom row; Table 2A).
Effective learning in animals with low A levels
Across the full set of 76 PDAPP mice, there were a number of
untreated animals with high A levels who nonetheless displayed
Figure3. Serial spatial learning: trials to criterionmeasure. Unlike conventionalmeasures of
water-maze spatial learning (which use escape latency), the measure of performance is the
number of trials taken to learn each spatial problem across five successive spatial problems. A,
B, Trials to criterion for the prevention study (experiment 1). Plot of performance for each
individual platform (A) and of mean performance across the five locations (B). Overall, the
PDAPP groups were impaired, and there was apparently no effect of immunization. C, D, Trials
to criterion for the reversal study. Plot shows performance for each individual platform and of
meanperformance across the five locations. Again, the PDAPPgroupswere impaired, and there
was no effect of immunization.
Figure 4. Serial spatial reversal learning: learning capacity measure. Additional training
continues for a full 10 d. The learning capacity measure is the total number of spatial locations
(problems) learned by each animal over this time. A, Prevention study. B, Reversal study. The
PDAPP mice were impaired, and there was no apparent impact of immunization.
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a high learning capacity score. This was not observed in the im-
munized PDAPP group. To the contrary, in this group, the ani-
mals that displayed particularly effective learning all had very low
total A andA42 levels (Fig. 5). Paradoxically, despite no overall
behavioral effect of immunization, there seemed to be (1) a
change in the distribution of animals as a function of levels of A
levels that (2) might be associated with a subtle but detectable
alteration in behavioral phenotype.
Accordingly, in the next step of the analysis, we examined all
immunized (n 41) and untreated (n 35) PDAPP animals by
stratifying them into subgroups reflecting their varied levels of
cortical and hippocampal A. A Pearson’s 2 test of the distribu-
tion of mice by category as shown in Table 3 was significant (for
cortical total A, 2  10.96, p  0.025; for hippocampal total
A,2 9.82, p 0.025).More critical is whether the number of
mice in the subgroups with lowest A levels differed as a function
of treatment. Pearson’s 2 tests for total A levels indicate that
immunization produced a significantly larger number of mice
with very low levels of A (for the subgroup of1000 ng/g total
A in the cortex: 2 4.02, p 0.05; for the subgroup of6000
ng/g total A in the hippocampus: 2  8.05, p  0.01). Al-
though thismerely confirms the effectiveness of immunization in
reducing A, this subgrouping by category enabled us to replot
the learning capacity data by subgroup, together with the same
data for the non-Tg animals (Fig. 6). The nine PDAPP animals
that showed cortical total A levels of 1000 ng/g formed a
subgroup that learned the series of platform locations at a rate
(8.78 0.43 locations in 10 d) that was not significantly different
fromnon-Tg controls (8.99 0.13 locations; NS) (Fig. 6A). A set
of orthogonal comparisons for all of the PDAPP animals also
revealed that the medium, high, and very high A subgroups did
not differwith respect to learning capacity (F 1) and performed
significantly worse than the very low A subgroup (F  10.9;
df 1/39; p 0.005). A similar analysis of the 13 PDAPP animals
showing hippocampal total A levels of 6000 ng/g also indi-
cated that they were not significantly different from non-Tg con-
trols (Fig. 6B). Orthogonal comparisons again revealed that the
medium, high, and very high subgroups did not differ (F  1),
with the very low subgroup (8.31 0.50 locations; n 13) per-
forming significantly better than these subgroups (F 9.90; df
1/39; p  0.005) and not differing from the non-Tg controls
(NS). Thus, immunization unmasks a relationship between A
levels and performance that, intriguingly, is not present in the
untreated animals.
A antibody titer responses and spatial learning
An additional immunological analysis was also conducted on the
serum anti-A titer responses in all animals tested in the water
maze. Comparison of the immunized animals in the prevention
and reversal experiments indicated that the longer period of A
treatment producedmore anti-A activity than the shorter treat-
ment (F  29.64; df  1/75; p  0.001) (Table 1). Immunized
PDAPPmice did not produce more anti-A activity than immu-
nized non-Tg mice (F  2.87; df  1/75; p  0.05). In parallel
with their higher antibody titer, the entire cohort of immunized
PDAPP animals exhibited a highly significant correlation be-
tween antibody titer and learning capacity (Spearman’s r 
0.443; p  0.005) (Table 2). No correlation between titer and
learning capacity was observed in non-Tg mice (Spearman’s r
0.116; p  0.4). Despite the overall relationship, the correlation
between antibody titer and learning capacity did not reach signif-
icance when immunized PDAPP mice from the prevention and
reversal groups were considered separately (Table 2). Although
immunized PDAPPmice in the prevention study exhibited lower
A levels and higher antibody titers compared with those in the
PDAPP reversal study (see above), no relationship was observed
between antibody titer and A levels (Table 2).
It has been reported recently that human patients with high
A antibody titer responses displayed less cognitive decline over
time than non-antibody responders (Gilman et al., 2005). We
Table 1. Total A and A42 levels in the cortex and hippocampus of PDAPPmice and amyloid titer response
A-immunized PDAPP MPL-AF-treated PDAPP % of decrease
Prevention Reversal Prevention Reversal Prevention Reversal
Cortex
Total A
n 17 24 17 18
Mean (ng/g) 2109 5188 6068 8342 65.2 37.8
SEM 464 876 1036 749
A42
n 17 24 17 18
Mean (ng/g) 2296 3779 5058 6902 54.6 45.3
SEM 506 631 799 562
Hippocampus
Total A
n 17 24 17 18
Mean (ng/g) 10379 18394 19199 22849 45.9 19.5
SEM 1904 2164 2562 1868
A42
n 17 24 17 18
Mean (ng/g) 10106 17744 19068 23026 47.0 22.9
SEM 1775 2034 2725 1983
A-immunized PDAPP A-immunized non-Tg
Prevention Reversal Prevention Reversal
Amyloid titer response
n 17 24 17 22
Mean 9662 2644 6769 1809
SEM 2365 214 860 196
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therefore analyzed spatial learning stratified by A antibody titer
responses in all immunized PDAPP mice. We sorted these ani-
mals into four categories: high responders (titers  5000),
midrange responders (1000  titers  5000), low responders
(100 titers 1000), and nonresponders (100). After either 5
or 9 month treatment with AN1792, most mice showed a high or
midrange level of anti-A titer response. Only two mice (one in
prevention study and one in reversal) displayed 1000 titer re-
sponses (low responders), and there were no nonresponders. An
ANOVA of learning capacity revealed a significant difference be-
tween these three different subgroups of immunized PDAPP an-
Figure 5. Correlation between A levels and learning capacity. A, B, Prevention study.
Analysis of the relationship between cortical (A) and hippocampal (B) total A levels and
learning capacity (LC) revealed a significant negative correlation. That is, animals with very low
A levels learned a higher number of platform locations in 10 d. C, D, Reversal study. A similar
analysis revealed a trend toward negative correlations between cortical and hippocampal A
levels and learning capacity, but these were not significant. E, F, Combined MPL-AF-treated
PDAPP animals. No relationships were observed between A levels and performance in
adjuvant- treated animals.
Table 2. Correlation coefficients between A and antibody titer levels and serial
spatial learning performance
Trials to criterion Learning capacity
Hippocampus
Total A
Prevention (n 17) 0.582* 0.624**
Reversal (n 24) 0.323 0.238
MPL-AF treated (n 35) 0.071 0.06
A42
Prevention 0.447 0.537
Reversal 0.367 0.284
MPL-AF treated 0.024 0.046
Cortex
Total A
Prevention 0.554* 0.573*
Reversal 0.281 0.334
MPL-AF treated 0.144 0.013
A42
Prevention 0.317 0.352
Reversal 0.375 0.421*
MPL-AF treated 0.145 0.028
Antibody titer
Prevention 0.231 0.317
Reversal 0.108 0.072
*p 0.05; **p 0.01.
Table 3. Distribution of numbers of PDAPPmice into categories as a function of
total A levels
Cortex
Total A (ng/g) 1000 2500 5000 5000 Total
A-immunized PDAPP 9* 9 12 11 41
MPL-AF-treated PDAPP 2 4 7 22 35
Hippocampus
Total A (ng/g) 6000 13000 20000 20000 Total
A-immunized PDAPP 13* 7 8 13 41
MPL-AF-treated PDAPP 2 4 10 19 35
*p 0.05.
Figure 6. Learning capacity as a function of A levels and A titers. A, The PDAPP mice
(immunized and untreated) were subdivided with respect to cortical A levels. These data
reveal that the subgroup with the very lowest A levels were indistinguishable from non-Tg
controls andbetter thanPDAPPmicewithhigherA levels.B, ThePDAPPmice (immunizedand
untreated)were subdividedwith respect to hippocampal A levels. The subgroupwith the very
lowest A levels was indistinguishable from non-Tg controls. C, The PDAPPmice (immunized)
were subdivided with respect to A titers. A relationship between antibody titer and perfor-
mance was observed, but the subgroup with the highest antibody response was still impaired
relative to non-Tg controls. Note an apparently exacerbated impairment in immunized mice
with a low antibody titer.
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imals (F 5.1; df 2/38; p 0.05) (Fig. 6C), indicating that A
titer high responders displayed better learning than midrange or
low responders. However, themeasure does not appear to be that
sensitive because the performance of the A titer high-
responders group did not differ significantly from that of non-
immunized PDAPPmice ( p 0.072) and, additionally, was still
slightly poorer than non-Tg controls ( p 0.05, two-tailed t test).
These data parallel those obtained using A levels but indicate
that a high antibody titer is no guarantee that learningwill be fully
rescued in PDAPP mice.
Discussion
Themain new finding is that a therapeutic rescue of spatial learn-
ing can occur in a subset of PDAPP mice in proportion to the
apparent effectiveness of immunization in suppressing A accu-
mulation in the brain. This positive finding emerges, however,
from a set of intriguingly paradoxical results. Neither short- nor
long-term immunization against human A had any overall ef-
fect on the rate of learning of a series of spatial tasks. However, we
anticipated at the outset that active immunization with A42 was
likely to have a varied effect across animals, achieving very low
levels of A only in a subset of our transgenic mice. This was
observed, notably in animals given long-term treatment begin-
ning at an age before overt amyloid plaque deposition. A signifi-
cant correlation was then unmasked between both total A and
A42 levels and performance. Moreover, subsets of immunized
PDAPPmicewith very lowA levels (n 9 for cortex, andn 13
for hippocampus) were behaviorally indistinguishable from
wild-type controls. There was no evidence of a relationship be-
tween learning ability and A levels in untreated PDAPP mice.
These findings are consistent with the notion that an active im-
munization therapy can be effective in an animal model of AD
that involves five to seven times overexpression of humanmutant
A.
Impact of immunization
The apparent “null result” in the overall analysis of the learning
data were not because immunizationwas ineffective. First, ELISA
measurements revealed a significantly lower level of total A and
A42 in A-immunized PDAPP comparedwithMPL-AF-treated
PDAPP animals, consistent with Schenk et al. (1999). Second,
immunized PDAPP mice showed an antibody titer response.
Third, there was significant redistribution of PDAPP mice be-
tween the A-treated and MPL-AF-treated groups when sorted
into subcategories defined according to both cortical and hip-
pocampal total A levels.
However, although a subset of PDAPPmicewith lowA levels
behaved like wild-type controls in the learning task, there was no
overall effect of immunization on cognitive function. This is puz-
zling because it would be expected that the overall group mean
for the treated PDAPP group should show at least a trend toward
being different from that of the untreated PDAPP group. The
absence of an overall effect of immunization might be explained
by the small number of immunized PDAPP mice with moderate
to highA levels that performed poorly in thewatermaze, raising
the specter of potential risks to function when using active
immunization.
Variation in the effectiveness of active immunization
A separate issue is the lack of a significant correlation betweenA
levels and performance in the control-treated PDAPP mice.
However, this is not surprising, and there has been recent interest
in distinguishing the potentially deleterious effects of distinct
forms on cognitive function. A significant correlation between
A levels and cognitive decline is not always found (Arriagada et
al., 1992; Hyman and Tanzi, 1992; Gomez-Isla et al., 1997; Gian-
nakopoulos et al., 2003; Guillozet et al., 2003). A possible limita-
tion in interpreting findings from mice with transgenic overex-
pression of human mutant A is that variation in levels that are
massively overexpressed may not be physiologically very mean-
ingful. However, if a treatment such as immunization is success-
ful in limiting the accumulation of A considerably, physiologi-
cally meaningful correlations may then be unmasked that could
be mechanistically insightful. If A is a causative factor in dys-
function of AD, it is reasonable to expect that “rescue” of cogni-
tive function could only occur if the putative therapy succeeded
in reducing A levels massively. This is because any lesser reduc-
tion would still leave individual mice with an overexpression of
the human mutant gene. On this view, finding rescue in only a
subset of PDAPPmice is arguably more consistent with the amy-
loid cascade hypothesis than findings in which functional rescue
is observed without such a large decrease (Hardy and Allsop,
1991; Selkoe, 1991, 2002). That we only observed significant res-
cue in the prevention study is also consistent with the notion that
maintaining very low A levels over a long period is better for
maintaining effective cognitive function. Thus, although the
number of animals (n  9 for cortical total A; n  13 for hip-
pocampal total A) in which these effects were observed is small
relative to the total number of immunized PDAPP animals tested
(n  41), there is a consistency about the behavioral and bio-
chemical phenotype that they displayed.
There is a second possibility for our failure to find an overall
positive immunization effect. A recent study has shown that a
soluble form of A assembly, termed A*56, contributes to cog-
nitive deficits in Tg2576 mice (Lesne et al., 2006). Because our
ELISA detected total A, both soluble and insoluble, we do not
know whether active A immunization effectively reduces the
soluble A oligomers as well. If so, a statistically detectable rela-
tionship may become apparent when the levels of this species are
reduced to near zero in a subset ofmice, i.e., only in those animals
that in our ELISAs would have shown very low levels of total A.
Our findings are therefore consistent with the emerging idea that
different species of A promote neuronal dysfunction in a differ-
ential manner. It would be valuable in future “proof-of-concept”
treatment studies to include analyses of different oligomeric spe-
cies of A.
Duration and timing of immunization
Significant rescue of learning capacity occurred in the prevention
study with administration of AN1792 at 7 months of age. It is
possible that even earlier A immunization, i.e.,2months as by
Schenk et al. (1999),might help prevent the functional damage to
synapses that has been linked to abnormal accumulation of A
(Selkoe, 2002; Kamenetz et al., 2003), whereas later A immuni-
zation would be expected to be less effective. Consistent with this
idea, active A immunization using 16-month-old presenilin
1/APP Tg mice with four biweekly immunizations revealed no
rescue of impaired learning when retesting in a radial-arm water
maze was performed at 18 months (Austin et al., 2003).
Comparison with other studies
The statistical power of animal studies requires careful consider-
ation, and we feel ethically justified in having used so many ani-
mals to complete this study. Only by running a large study (n
150) were we able to unmask a subtle impact that A immuniza-
tion. Recent criticism of some animal therapeutic studies (e.g.,
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models of stroke) has focused on the use of overly small group
sizes (Sandercock and Roberts, 2002; Pound et al., 2004). We
share this concern about “under-powered” animal studies. The
recent report by Billings et al. (2005) using250 mice is consis-
tent with this perspective.
The variability of A levels in treated PDAPP animals is also
relevant. Genetic background can significantly affect Ametab-
olism and A deposition in different mouse strains expressing
similar levels of APP holoprotein (Lehman et al., 2003). Thus, the
more complex genetic makeup of the triple-cross background
strain used with the PDAPP mice may contribute to their vari-
ability in A metabolism and deposition and reaction to
immunization.
Our findings may seem inconsistent with those of previously
published reports for which positive overall effects of immuniza-
tion were seen with water maze reversal learning, a radial water
maze task, and novel object recognition (Janus et al., 2000; Mor-
gan et al., 2000; Dodart et al., 2002; Kotilinek et al., 2002; Billings
et al., 2005; Comery et al., 2005; Hartman et al., 2005;Maier et al.,
2006; Wilcock et al., 2006). Passive A immunotherapy may be
more effective in rescuing cognitive deficits in APP Tgmice (Do-
dart et al., 2002; Kotilinek et al., 2002; Billings et al., 2005; Comery
et al., 2005; Hartman et al., 2005; Wilcock et al., 2006). The dis-
crepancies between our and the other studies may reflect group
sizes, which were typically smaller in earlier studies, the presence
of an age-independent deficit in PDAPP mice that may be unre-
lated to A levels, the effectiveness of active versus passive A
immunization, and/or the differential sensitivity of various be-
havioral tasks. The serial spatial learning task (Chen et al., 2000)
is, for example, more sensitive in revealing age-related learning
deficits than a standard referencememory training protocol (Jus-
tice andMotter, 1997). It is for this reason that we have argued for
the use of episodic-like tasks such as the radial-arm water maze
and serial spatial learning task in phase 1 studies (Morgan et al.,
2000; Morris, 2001).
Implications with respect to human studies
Because of the unexpected meningoencephalitis caused by
AN1792, the first clinical immunization study of AD patients was
halted (Schenk, 2002). Neuropathological observations indicate
that immunization is associated with reduced plaques in the hu-
man brain (Nicoll et al., 2003). A subset of 20 AN1792-
immunized patients that were identified as A titer responders in
the Zurich cohort of the AN1792 clinical trial showed a reduced
rate of decline of cognitive function (Hock et al., 2003). It has
been reported that, although analysis of the full 300 patients of
the AN1792 study failed to reveal overall differences between
placebo and immunized patients across a range of cognitive tests,
a subset of 59 patients that were antibody responders showed a
lesser decline, relative to placebo controls, in one neuropsycho-
logical test battery (Gilman et al., 2005). In our animal study, we
find that a subset of immunized PDAPP mice with very high A
titer responses displayed better spatial learning than low A titer
responders. Furthermore, our findings suggest that active A
immunization can successfully restore spatial learning in amouse
model of AD if the brain A levels fail to accumulate. Together,
human and animal studies collectively provide additional
grounds for confidence that immunization is a viable approach to
novel therapeutics for AD.
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